The first-in-human trial assessing the safety and efficacy of the PRIMA photovoltaic retinal stimulation microchip for severe central vision impairment due to dry age-related macular degeneration showed positive outcomes at 4 years.
“The trial data show that the implantation of PRIMA is feasible and well tolerated in all five study participants, with no reduction of natural peripheral visual function after 48 months,” Pixium Vision said in a press release.
Patients experienced a clinically meaningful visual acuity improvement of up to eight lines and were able to recognize letters